Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Thaçi, J. Humeniuk, Y. Frambach, R. Bissonnette, J. Goodman, S. Shevade, Y. Gong, C. Papavassilis (2015)
Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)British Journal of Dermatology, 173
A. Nast, W. Boehncke, U. Mrowietz, H. Ockenfels, S. Philipp, K. Reich, T. Rosenbach, Adel Sammain, M. Schlaeger, M. Sebastian, Wolfram Sterry, V. Streit, M. Augustin, R. Erdmann, Joachim Klaus, J. Koza, Siegrid Muller, H. Orzechowski, S. Rosumeck, G. Schmid‐Ott, T. Weberschock, B. Rzany (2012)
German S3-guidelines on the treatment of psoriasis vulgaris (short version)Archives of Dermatological Research, 304
Nast (2011)
S3-guidelines for the treatment of psoriasis vulgaris update 2011J Dtsch Dermatol Ges, 9
M. Augustin, G. Glaeske, M. Radtke, E. Christophers, K. Reich, I. Schäfer (2010)
Epidemiology and comorbidity of psoriasis in childrenBritish Journal of Dermatology, 162
M. Augustin, L. Eissing, A. Langenbruch, Alexander Enk, T. Luger, D. Maaßen, U. Mrowietz, Kristian Reich, Michael Reusch, Klaus Strömer, Diamant Thaçi, R. Kiedrowski, M. Radtke (2016)
The German National Program on Psoriasis Health Care 2005–2015: results and experiencesArchives of Dermatological Research, 308
U. Mrowietz, C. Leonardi, G. Girolomoni, D. Toth, A. Morita, Shyamal Balki, J. Szepietowski, P. Regnault, H. Thurston, C. Papavassilis (2015)
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).Journal of the American Academy of Dermatology, 73 1
R. Parisi, D. Symmons, C. Griffiths, D. Ashcroft (2013)
Global epidemiology of psoriasis: a systematic review of incidence and prevalence.The Journal of investigative dermatology, 133 2
M. Schlander, O. Schwarz, M. Viapiano, N. Bonauer (2008)
PSS21 ADMINISTRATIVE PREVALENCE OF PSORIASIS IN GERMANYValue in Health, 11
U. Mrowietz, Emgj Jong, K. Kragballe, R. Langley, A. Nast, L. Puig, K. Reich, Jochen Schmitt, R. Warren (2014)
A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasisJournal of the European Academy of Dermatology and Venereology, 28
S. Kurd, A. Troxel, P. Crits-Christoph, J. Gelfand (2010)
The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.Archives of dermatology, 146 8
M. Noe, D. Shin, J. Doshi, D. Margolis, J. Gelfand (2019)
Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records DatabaseJournal of drugs in dermatology : JDD, 18 8
R. Langley, B. Elewski, M. Lebwohl, K. Reich, C. Griffiths, K. Papp, L. Puig, H. Nakagawa, L. Spelman, B. Sigurgeirsson, E. Rivas, T. Tsai, N. Wasel, S. Tyring, T. Salko, I. Hampele, M. Notter, A. Karpov, S. Helou, C. Papavassilis (2014)
Secukinumab in plaque psoriasis--results of two phase 3 trials.The New England journal of medicine, 371 4
Carle Paul, J. Lacour, L. Tedremets, K. Kreutzer, S. Jazayeri, S. Adams, Carrie Guindon, R. You, C. Papavassilis (2015)
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)Journal of the European Academy of Dermatology and Venereology, 29
A. Blauvelt, J. Prinz, A. Gottlieb, K. Kingo, H. Sofen, M. Ruer-Mulard, V. Singh, R. Pathan, C. Papavassilis, S. Cooper (2015)
Secukinumab administration by pre‐filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)British Journal of Dermatology, 172
A. Reich, E. Hrehorów, J. Szepietowski (2010)
Pruritus is an important factor negatively influencing the well-being of psoriatic patients.Acta dermato-venereologica, 90 3
V. Strand, Veronika Sharp, A. Koenig, G. Park, Yifei Shi, Brian Wang, D. Zack, D. Fiorentino (2012)
Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatmentAnnals of the Rheumatic Diseases, 71
R. Langley, G. Krueger, C. Griffiths (2005)
Psoriasis: epidemiology, clinical features, and quality of lifeAnnals of the Rheumatic Diseases, 64
A. Langenbruch, M. Radtke, A. Jacobi, S. Purwins, K. Haack, K. Reich, K. Stroemer, U. Mrowietz, M. Augustin (2016)
Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”Archives of Dermatological Research, 308
A. Kimball, C. Jacobson, S. Weiss, M. Vreeland, Ying Wu (2005)
The Psychosocial Burden of PsoriasisAmerican Journal of Clinical Dermatology, 6
IntroductionPsoriasis is a chronic inflammatory, immune‐mediated skin disease affecting 1–3% of the industrialized population. There are several treatment options available for moderate to severe psoriasis that can provide improvements in clinical assessments of skin symptoms [e.g. Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI)]. The disease is associated with both physical and psychological impairments, and hence, optimal control requires adherence to continuous treatment.PROSPECT (Observational, Descriptive Study of Prior and Concomitant Psoriasis Treatments in Subjects Receiving Secukinumab in the Routine Treatment of Moderate to Severe Plaque‐type Psoriasis; EUPAS10715) is a descriptive study designed to assess prior and concomitant use of psoriasis treatments in subjects receiving secukinumab, and the duration of transition periods from prior treatments to secukinumab treatment in Germany. Previous studies report the prevalence of psoriasis for individuals of all ages in Germany as 2.00% (95% confidence internal (CI): 1.98–2.20) and 2.53% (95% CI: 2.50–2.56). German and European treatment guidelines for psoriasis recommend combinations of various psoriasis treatments for selected subjects and purposes. For example, topical treatments are often combined with both conventional systemic treatments and biologics, and conventional systemic treatments are sometimes combined with biologics. A recent international consensus report
Journal of the European Academy of Dermatology & Venereology – Wiley
Published: Jan 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.